株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EpiCast Report:血友病の疫学的予測

Hemophilia: Epidemiology Forecast to 2028

発行 GlobalData 商品コード 344637
出版日 ページ情報 英文 48 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
EpiCast Report:血友病の疫学的予測 Hemophilia: Epidemiology Forecast to 2028
出版日: 2019年07月31日 ページ情報: 英文 48 Pages
概要

当レポートでは、世界の主要9ヶ国 (米国、ドイツ、フランス、イタリア、スペイン、英国、日本、アルゼンチン、中国) における血友病A・Bの発症状況と今後の見通しについて分析し、疾患の特徴や、現在の有病者の発症状況、今後10年間の有病件数の予測値などを調査・推計しております。

第1章 目次

第2章 イントロダクション

  • 疾患の概略
  • 関連分析
  • 刊行予定の関連分析

第3章 疫学的予測

  • 疾患の背景事情
  • リスク要因と共存症
  • 世界的な傾向
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法
  • 血友病Aの疫学的予測
    • 診断済みの有病者数
    • 診断済みの有病者数:年齢別
    • 診断済みの有病者数:男女別
    • 診断済みの有病者数 (年齢調整済み)
  • 血友病Bの疫学的予測
    • 診断済みの有病者数
    • 診断済みの有病者数:年齢別
    • 診断済みの有病者数:男女別
    • 診断済みの有病者数 (年齢調整済み)
  • 血友病A・Bの疫学的予測
    • 診断済みの有病者数
    • 診断済みの有病者数:男女別
  • 議論
    • 疫学的予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表一覧

図表

List of Tables

  • Table 1: Relationship of Bleeding Severity with Clotting Factor Level.
  • Table 2: Comorbidities for Hemophilia

List of Figures

  • Figure 1: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, 2018 and 2028
  • Figure 2: 8MM, Diagnosed Prevalent Cases of Acquired Hemophilia, Both Sexes, All Ages, 2018 and 2028
  • Figure 3: 8MM, Diagnose
目次
Product Code: GDHCER207-19

Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (Hemophilia A) or factor IX (Hemophilia B). Hemophilia is a rare, genetic, potentially life-threatening bleeding disorder. The clinical presentation of hemophilia ranges from mild, to moderate, to severe stages, depending on the residual level of the circulating factor.

The diagnosed prevalent cases of hemophilia in the US are likely to exceed that of China over the next decade, with 18,723 cases in the US in 2028 as compared to 14,186 cases in China in 2028, due to higher hemophilia knowledge in the US as compared to China.

Diagnosed prevalent cases of Hemophilia A and Hemophilia B is forecasts to increase across the eight major markets (US, France, Germany, Italy, Spain, UK, Japan, and China), from 67,051 cases in 2018 and 67,678 cases in 2028, at an Annual Growth Rate (AGR) of 0.09%. The US will have the highest number of diagnosed prevalent cases of hemophilia A and Hemophilia B among the eight major markets (US, France, Germany, Italy, Spain, UK, Japan, and China), while Spain will have the lowest.

Epidemiologists forecast an increase in the diagnosed prevalent cases of acquired hemophilia from 2,163 diagnosed prevalent cases in 2018 to 2,215 diagnosed prevalent cases in 2028, with an AGR of 0.24% during the forecast period. China will have the highest number of diagnosed prevalent cases of acquired hemophilia among the eight major markets, while Spain will have the lowest.

The latest report "Hemophilia: Epidemiology Forecast to 2028", reveals that the relatively stable trend in the diagnosed prevalent cases of hemophilia over the next decade is partly attributable to changing population demographics in the next ten years. The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and Hemophilia B), sex, and age (for all ages) in these markets. The diagnosed prevalent cases of hemophilia A and hemophilia B are further segmented by severity (mild, moderate, and severe), inhibitors status, inhibitors severity (high responding and low responding), and type of treatment (prophylaxis and on-demand). Additionally, the report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of acquired hemophilia.

Scope

  • The Hemophilia Epidemiology Report provides an overview of the risk factors and global trends of hemophilia in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
  • The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and hemophilia B), sex, and age (for all ages) in these markets. The diagnosed prevalent cases of hemophilia A and hemophilia B are further segmented by severity (mild, moderate, and severe), inhibitors status, inhibitors severity (high responding and low responding), and type of treatment (prophylaxis and on-demand). Additionally, the report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of acquired hemophilia.
  • The hemophilia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Hemophilia Epidemiology report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global hemophilia market.
  • Quantify patient populations in the global hemophilia market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for hemophilia therapeutics in each of the markets covered.
  • Understand magnitude of hemophilia population by severity.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Hemophilia: Executive Summary

  • 2.1 Related Reports
  • 2.2 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
    • 3.4.3 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
    • 3.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
    • 3.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitor Status
    • 3.4.6 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
    • 3.4.7 Type of Treatment Among Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
    • 3.4.8 Diagnosed Prevalent Cases of Acquired Hemophilia
  • 3.5 Epidemiological Forecast for Hemophilia A (2018-2028)
    • 3.5.1 Diagnosed Prevalent Cases of Hemophilia A
    • 3.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A
    • 3.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A
    • 3.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity
    • 3.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors
  • 3.6 Epidemiological Forecast for Hemophilia B (2018-2028)
    • 3.6.1 Diagnosed Prevalent Cases of Hemophilia B
    • 3.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia B
    • 3.6.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia B
    • 3.6.4 Diagnosed Prevalent Cases of Hemophilia B by Severity
    • 3.6.5 Diagnosed Prevalent Cases of Hemophilia B with Inhibitors
  • 3.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2018-2028)
    • 3.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
    • 3.7.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
    • 3.7.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
    • 3.7.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
    • 3.7.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors
    • 3.7.6 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
    • 3.7.7 Type of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
    • 3.7.8 Diagnosed Prevalent Cases of Acquired Hemophilia
  • 3.8 Discussion
    • 3.8.1 Epidemiological Forecast Insight
    • 3.8.2 Limitations of Analysis
    • 3.8.3 Strengths of Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer
Back to Top